Mnemo Therapeutics Announces €75 million Series A to Accelerate Next Generation Integrated CAR-T and Epigenetic Targeting Platform
June 16, 2021
Financing led by Casdin Capital, Sofinnova Partners – initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing